Notice2023-02772
Prospective Grant of Exclusive Patent License: Novel Therapeutics for the Treatment of Neurodegenerative Disorders
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
February 9, 2023
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The National Institute of Neurological Disorders and Stroke ("NINDS"), an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive, sublicensable patent license to University College London Business, Ltd. ("UCLB"), incorporated in England and Wales under company registration number 02776963 whose registered office address is University College London, Gower Street, London WC1E 6BT, United Kingdom, for NINDS's rights to the patent applications listed in the Supplementary Information section of this notice. UCLB is the technology transfer company of the University College London ("UCL"), a non-profit research institution located in London, United Kingdom.
Full Text
<html>
<head>
<title>Federal Register, Volume 88 Issue 27 (Thursday, February 9, 2023)</title>
</head>
<body><pre>
[Federal Register Volume 88, Number 27 (Thursday, February 9, 2023)]
[Notices]
[Pages 8440-8441]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2023-02772]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive Patent License: Novel Therapeutics
for the Treatment of Neurodegenerative Disorders
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Institute of Neurological Disorders and Stroke
(``NINDS''), an institute of the National Institutes of Health,
Department of Health and Human Services, is contemplating the grant of
an exclusive, sublicensable patent license to University College London
Business, Ltd. (``UCLB''), incorporated in England and Wales under
company registration number 02776963 whose registered office address is
University College
[[Page 8441]]
London, Gower Street, London WC1E 6BT, United Kingdom, for NINDS's
rights to the patent applications listed in the Supplementary
Information section of this notice. UCLB is the technology transfer
company of the University College London (``UCL''), a non-profit
research institution located in London, United Kingdom.
DATES: Only written comments and/or applications for a license which
are received by the National Institute of Neurological Disorders and
Stroke Technology Transer Office by February 24, 2023 will be
considered.
ADDRESSES: Requests for copies of the patent applications, inquiries,
and comments relating to the contemplated exclusive patent license
should be directed to: Lola Olufemi, Ph.D., Senior Technology Portfolio
Manager; NINDS Technology Transfer Office, at Telephone: (301) 451-3748
or Email: <a href="/cdn-cgi/l/email-protection#84ebe8f1e2e1e9edebebc4eaedecaae3ebf2"><span class="__cf_email__" data-cfemail="f49b98819291999d9b9bb49a9d9cda939b82">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION: The following and all continuing U.S. and
foreign patents/patent applications thereof are the intellectual
properties to be licensed under the prospective agreement to UCLB
include: PCT patent application number PCT/EP2021/084908, entitled
``Novel Therapeutics for the treatment of neurodegenerative disorders''
(claiming priority to GB 2019418.9, filed December 9, 2020) filed
December 9, 2021 (HHS Reference E-198-2021) and GB patent application
number 2117758.9, entitled, ``Therapeutics for the treatment of
neurodegenerative disorders'' (HHS Reference E-071-2023), filed
December 9, 2021.
With respect to the inventions described and claimed in the patent
applications PCT/EP2021/084908 and GB 2117758.9, each of the inventors
has assigned their rights to their respective employers or an entity
which manages the intellectual property for their employer (The United
States of America, UCL and UCLB). The prospective license will be for
the purpose of consolidating the patent rights with UCLB, the co-owner
of said rights, for commercial development and marketing. Consolidation
of these co-owned rights is intended to expedite development of the
invention, consistent with the goals of the Bayh-Dole Act codified as
35 U.S.C. 200-212.
The prospective patent license will be worldwide, exclusive, and
may be limited to those fields of use commensurate in scope with the
patent rights. It will be sublicensable, and any sublicenses granted by
UCLB will be subject to the provisions of 37 CFR part 404.
The technologies describe antisense oligonucleotides (ASOs) that
are capable of modulating splicing by preventing inclusion of an UNC13A
cryptic exon into an UNC13A mature mRNA. Guide RNAs including the ASO,
and viral vectors expressing the ASO are also described. Such ASOs and
guide RNAs may be used as a medicament, for example, to treat
neurodegenerative disorders, particularly those associated with TDP-43
pathology.
This notice is made pursuant to 35 U.S.C. 209 and 37 CFR part 404.
The prospective exclusive patent license will include terms for the
sharing of royalty income with NINDS from commercial sublicenses of the
patent rights and may be granted unless within fifteen (15) days from
the date of this published notice the NINDS receives written evidence
and argument that establishes that the grant of the license would not
be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part
404.
Complete applications for a license that are timely filed in
response to this notice will be treated as objections to the grant of
the contemplated exclusive patent license. In response to this Notice,
the public may file comments or objections. Comments and objections,
other than those in the form of a license application, will not be
treated confidentially, and may be made publicly available.
License applications submitted in response to this Notice will be
presumed to contain business confidential information and any release
of information from these license applications will be made only as
required and upon a request under the Freedom of Information Act, 5
U.S.C 552.
Susan E Ano,
Branch Chief, Technology Transfer Branch, National Institute of
Neurological Disorders and Stroke.
[FR Doc. 2023-02772 Filed 2-8-23; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on February 9, 2023.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.